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A b s t r a c t
Introduction: Cardiovascular disease is still a leading cause of death in Po-
land and across Europe. The aim of this study was to assess the attainment 
of the main treatment goals for secondary cardiovascular prevention in cor-
onary patients with or without diabetes mellitus (DM) in Poland.
Material and methods: The study group included 1026 patients (65.5 ±9 y.o.; 
males: 72%) included at least 6 months after the index hospitalisation for 
myocardial infarction, unstable angina, elective percutaneous coronary in-
tervention or coronary artery bypass surgery. The target and treatment goals 
were defined according to the 2016 European Society of Cardiology guide-
lines on cardiovascular prevention.
Results: Patients with DM (n = 332; 32%) were slightly older compared to 
non-diabetic (n = 694) individuals (67.2 ±7 vs. 64.6 ±9 years old; p < 0.0001). 
The DM goal was achieved in 196 patients (60%). The rate of primary (LDL: 
51% vs. 35%; p < 0.0001) and secondary (non-HDL: 56% vs. 48%; p < 0.02) 
goal attainment was higher in DM(+) compared to DM(–) patients. The rate 
of target blood pressure was lower in DM(+) than in normoglycemic patients 
(52% vs. 61% at < 140/90 mm Hg, p < 0.01. As expected, goal achievement 
of normal weight (9.5% vs. 19%; p < 0.0001) and waist circumference (7% vs. 
15%; p < 0.001) was lower in diabetic patients and the rate of regular physi-
cal activity was similar (DM+ 12% vs. DM– 14%; p = ns). Finally, there was no 
difference in active smokers (DM+ 23% vs. DM– 22%; p = ns).
Conclusions: Great majority of Polish patients in secondary prevention do not 
achieve treatment goals. Although lipid goals attainment is better in DM and the 
rate of smokers is similar, the management of all risk factors needs to be improved.
Key words: mischemic heart disease, coronary artery disease, diabetes, 
obesity, secondary prevention, goal attainment.
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Introduction
Cardiovascular disease (CVD) is still a  leading 
cause of  death in Poland and across Europe  [1]. 
Diabetes mellitus (DM) is a  main risk factor for 
coronary artery disease (CAD) [2], which is associ-
ated with a more complex multivessel CAD [3] and 
worse clinical prognosis  [4]. Therefore patients 
with CAD and DM require optimal medical therapy 
and high rates of  treatment goal attainment  [5]. 
Despite recent progress in methods of  invasive 
treatment of  CAD and its better availability  [6], 
the one-year mortality rate following myocardial 
infarction is still relatively high – 10% [7, 8]. Sev-
eral studies and registries suggest that more ef-
forts should be made to improve secondary CVD 
prevention to achieve better control of risk factors 
and lifestyle modifications [9–12].
The European Society of Cardiology (ESC) pub-
lished guidelines on CVD prevention in clinical prac-
tice in 2016 [5] promoting clinical recommendations 
and providing target treatment goals. The available 
data on the recent efficacy of secondary prevention 
in Poland are scarce and limited to single measures. 
Therefore, the  aim of  our study was to provide 
a  comprehensive assessment of  the  attainment 
of main treatment goals in secondary prevention in 
coronary patients with or without DM.
Material and methods
POLASPIRE was a  multicenter, cross-sectional 
study performed among Polish patients from 4 geo- 
 graphical areas (Kraków, Katowice, Bialystok, War-
szawa) and 14 departments of  cardiology repre-
senting various reference levels, including depart-
ments within medical universities and secondary 
care hospitals. The study had two parts performed 
independently in all departments (2017–2018): 
retrospective identification of  patients (eligibility 
criteria) from hospital discharge lists of 14 depart-
ments and a  prospective visit of  study patients 
performed in leading centers of 4 geographical re-
gions. All consecutive patients, men and women 
(≥ 18 years and < 80 years of age at the time of their 
index event or procedure) hospitalized more than 
6 months earlier in one of the 14 departments for 
acute myocardial infarction, unstable angina, elec-
tive percutaneous coronary intervention (PCI) or 
coronary artery bypass surgery (CABG) were iden-
tified and invited for a  study visit. The  aim was 
to obtain prospective survey data on at least 200 
patients in each geographical area using similar 
standardized methods and instruments accord-
ing to the  manufacturer’s manual in all centers. 
All parts of the study were performed by centrally 
trained research staff. Retrospective data regard-
ing demographic information, clinical diagnoses, 
CV diseases and risk factors or laboratory tests 
were obtained from medical records. The study vis-
it provided updated data on CV risk factors, attain-
ment of treatment goals, medications and lifestyle. 
The visit included an interview with a patient using 
a detailed questionnaires of the European Action 
on Secondary Prevention through Intervention to 
Reduce Events (EUROASPIRE V) registry translated 
and validated for Poland. Additional available med-
ical records were used for information on CV risk 
factors and current treatment. Moreover, the  fol-
lowing measurements were performed during 
the visit: office blood pressure (mean value from 
two measurements), height and weight, waist cir-
cumference. Fasting venous blood was drawn for 
serum glycated hemoglobin (HbA1c), total choles-
terol (TCH), high-density lipoprotein (HDL-C), tri-
glycerides (TG) and low-density lipoprotein (LDL-C) 
was calculated according to Friedewald’s formu-
la [13]. Definitions of risk factors and target treat-
ment goals were based on the 2016 European Soci-
ety of Cardiology guidelines on CVD prevention [5].
The diagnosis of dyslipidaemia was defined as 
abnormal plasma lipid levels (TCH  >  190 mg/dl, 
LDL cholesterol  >  115 mg/dl, TG  >  150 mg/dl, 
HDL cholesterol < 40 mg/dl in men and < 50 mg/dl 
in women) or prior diagnosis and/or treat-
ment  [14]. Overweight was defined as a  body 
mass index (BMI) ≥ 25  <  30 kg/m2 and obesity 
as a  BMI ≥ 30 kg/m². Waist circumference (WC) 
was measured using a  tape applied at the point 
midway in the mid-axillary line between the low-
est rim of the rib cage and the superior iliac crest 
of  the  patient standing. Abdominal overweight 
was defined as a WC of ≥ 80 cm for women and 
≥ 94 cm for men. Arterial hypertension was de-
fined as systolic blood pressure (SBP) ≥ 140 mm Hg 
and/or diastolic blood pressure (DBP) ≥ 90 mm Hg. 
Smoking was defined at the  time of  interview 
and physical activity was estimated in an  inter-
view-based questionnaire. Chronic kidney dis-
ease was included in the patient’s characteristics 
based on a  prior diagnosis and/or treatment on 
the  retrospective discharge list from the  index 
hospitalization  [15]. Total cholesterol, HDL-C and 
TG were analyzed in serum, and HbA1c in whole 
blood. The  main aim and the  outcome measure 
of this analysis was the rate of patients with IHD 
and DM (known and treated since the index hos-
pitalization) achieving the  lifestyle, risk factors 
and therapeutic targets in comparison with indi-
viduals with IHD and not known DM. The  study 
group was divided into two subgroups with (DM+) 
and without known DM (DM–) based on the retro-
spective medical records, including the discharge 
hospital documents (diagnosis and/or treatment).
The following goals were defined according to the 
2016 guidelines [5]: controlled DM (HbA1c < 7.0%), 
lipid primary (LDL < 70 mg/dl) and secondary goal 
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(non-HDL  <  100 mg/dl), normal blood pressure 
(SBP < 140 and DBP < 90 mm Hg for all), normal 
BMI (20.0–25.0 kg/m), normal WC (women < 80 cm 
or men < 94 cm), smoking abstinence and regular 
physical activity with an equivalent of at least inten-
sive activity for 20 minutes twice a week. The total 
number of attained goals was the sum of the above 
defined. An additional result for the attainment of 
BP target  <  140/85 mm Hg was provided in the 
group with DM.
The coordinators of 4 geographical areas were 
responsible for obtaining Local Ethics Committees 
approvals and a  written informed consent form 
was obtained from all the participants and stored 
in the patient’s file.
Statistical analyses
All results presented in the text, tables and fig-
ures are expressed as means ± standard deviation 
or number and percentage. Figure 3 is the excep-
tion and presents a box-and-whisker plot with 
medians, interquartile range and extreme values. 
The  normality of  distributions was analyzed us-
ing the Kolmogorov-Smirnov test. Baseline clinical 
parameters and the measures were compared be-
tween the subgroups using the t-tests for normally 
distributed continuous variables (Student’s t-test); 
in case of non-normal distribution, the Mann-Whit-
ney U test was used. The Pearson χ2 test was ap-
plied to all categorical variables. A value p < 0.05 
was considered statistically significant. Statistical 
analysis was undertaken using MedCalc software 
(version 19.0.5, Belgium).
Results
Clinical characteristics in patients  
with and without diabetes mellitus 
The study group included 1026 patients (65.5 
±9 years old, male/female: 72%/28%), who accept-
ed the invitation for the interview and the exam-
ination > 6 months after the index hospitalization 
for acute myocardial infarction (39%), unstable 
angina (22%), elective percutaneous coronary in-
tervention (35%) or coronary artery bypass surgery 
(4%). The  study group represented a  population 
of  a  very-high CV risk with several risk factors: 
dyslipidemia (100%), hypertension (81%), DM 
(32%), overweight (42.5%), obesity (43%) and ac-
tive tobacco smoking (31%). Patients with known 
DM at the  index hospitalization were included in 
the DM(+) group.
Patients DM(+) (n  =  332; 32%) were slightly 
older compared to DM(–) individuals (67.2 ±7 vs. 
64.6 ±9 years; p  <  0.0001) with similar gender 
distribution (p = ns). Most patients with DM used 
oral antihyperglycemic medications (79%) with 
a minority treated with insulin (10%) or both (11%). 
The mean number of antihypertensive drugs was 
significantly increased in patients with DM (DM+ 
Table I. Clinical characteristics of study patients with and without diabetes mellitus
Parameter Ischemic heart disease
Diabetes (+) (n = 332) Diabetes (–) (n = 694) P-value
Clinical characteristics
Patients 332 (32%) 694 (68%) < 0.0001
Age [years] 67.2 ±7 64.6 ±9 < 0.0001
Males 233 (70%) 499 (72%) 0.6
Dyslipidemia 332 (100%) 694 (100%) 1.0
Hypertension 298 (89.8%) 637 (91.7%) 0.3
Overweight 101 (31%) 303 (43%) 0.0001
Obesity 194 (59%) 260 (37%) 0.0001
Chronic kidney disease 33 (9.6%) 32 (4.6%) 0.002
Lipid-lowering treatment
Statins 289 (89%) 623 (90%) 0.6
Atorvastatin 218 (65%) 441 (63%) 0.5
Rosuvastatin 64 (19%) 160 (23%) 0.14
Simvastatin 14 (4.2%) 19 (2.7%) 0.2
Fibrates 19 (5.8%) 17 (2.4%) 0.005
Ezetimibe 7 (2.1%) 20 (2.9%) 0.45
Data are presented as mean ± SD or No. (%).
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There were 44 patients (6.3%) with undiagnosed 
DM (no DM or antihyperglycemic agents in medical 
records of the index event). Most of them (41) were 
diagnosed with DM in the  outpatient clinics (oral 
glucose tolerance test or fasting plasma glucose) 
and were given oral antihyperglycemic drugs. More-
over, 246 patients (35%) in the DM(–) group had in-
creased fasting plasma glucose at the prospective 
study visit suggestive of impaired fasting glucose.
Treatment goal attainment
The follow-up visit showed that patients with 
DM had significantly higher SBP, BMI, WC, TG and 
lower LDL-C and HDL-C compared to individuals 
without DM (Table II).
The attainment of particular treatment goals is 
shown in Figure 1. In brief, the glycemic goal was 
achieved in 196 patients (60%) (Figure 2). The rates 
of primary (LDL-C: 51% vs. 35%; p < 0.0001) and 
secondary (non-HDL-C: 56% vs. 48%; p < 0.02) lipid 
goal attainment were higher in DM(+) compared to 
DM(–) patients, but they had a smaller proportion 
of normal TG levels (65% vs. 76%; p < 0.001) (Fig-
ure 3). The rate of blood pressure < 140/90 mm Hg 
was lower in DM(+) than in normoglycemic pa-
tients (52% vs. 61%; p < 0.01). When the recom-
mended target for patients with DM was used 
(< 140/85 mm Hg), the rate of target BP in the DM 
group was even lower (45%). As expected, goal 
achievement of  normal weight (9.5% vs. 19%; 
p < 0.0001) and waist circumference (7% vs. 15%; 
p < 0.001) were lower in diabetic patients. The rate 
of  individuals with regular physical activity was 
similar and low (DM(+): 12% vs. DM(–): 14%; p = ns). 
Finally, the proportions of active smokers were com-
parable but unacceptably high in both groups (DM(+): 
23% vs.. DM(–): 22%; p = ns) (Figure 1).
The total number of achieved goals was simi-
lar between both subgroups (DM(+): 2.56 ±1.3 vs. 
DM(–): 2.6 ±1.2; p = 0.6) (Figure 4). However, there 
was a small difference in total goal achievement 
2.93 ±0.66 vs. DM– 2.54 ±0.8; p < 0.0001). The clin-
ical characteristics of  the  study group based on 
the retrospective hospital discharge list and med-
ical records with the lipid-lowering treatment are 
presented in Table I.
Table II. Clinical assessment on follow-up visit in patients with and without diabetes mellitus
Parameter  Ischemic heart disease
Diabetes (+) (n = 332) Diabetes (–) (n = 694) P-value
Systolic blood pressure [mm Hg] 138 ±21 132 ±18 < 0.0001
Diastolic blood pressure [mm Hg] 80 ±12 80 ±10 1.0
Low-density lipoprotein cholesterol [mg/dl] 79 ±31 86 ±37 0.003
High-density lipoprotein cholesterol [mg/dl] 47.6 ±14.3 52 ±14.5 < 0.0001
Triglycerides [mg/dl] 143 ±77 125 ±90 0.002
Body mass index [kg/m²] 30.1 ±4.6 28.9 ±4.5 0.0001
Waist circumference [cm] 105.6 ±11.7 100.8 ±13 < 0.0001
Data are presented as mean ± SD or No. (%).
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Figure 1. Therapeutic goal achievements in patients 
with and without diabetes mellitus
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Figure 2. Diabetes control: HbA1c in patients with 
diabetes mellitus with the relative frequency in the 
study group
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among male patients (DM(+): 2.97 ±4.7 vs. DM(–): 
2.77 ±1.4; p < 0.001) with no differences between 
female groups (DM(+) 2.55 ±3.2 vs. DM(–) 2.54 
±1.2; p = 0.9).
Figure 5 presents rates of patients of both groups 
reaching particular number of treatment goals.
Most patients with DM reported having a reg-
ular glucose check-up (88%) and a  regular BP 
measure (DM+: 91% vs. DM–: 81%; p < 0.05). Only 
one-third of patients reported following a specif-
ic lipid-lowering diet (DM+: 33% vs. DM–: 28%; 
p < 0.05). The particular lipid-lowering treatment 
is presented in Table I. The proportion of patients 
who were able to quit smoking just after the index 
event was higher in the DM(–) group (DM+: 28.5% 
vs. 36.6%; p < 0.05).
The proportion of  patients who attempted 
to attain their weight was higher in DM patients 
(DM(+): 67.8% vs. DM(–): 60%; p = 0.01) and that 
Figure 4. Total number of the main therapeutic goals  
attained. Box-and-whisker plot showing median, inter- 
quartile range (1st and 3rd quartiles) and extreme 
values. Therapeutic goals: low-density lipoproteins 
cholesterol < 70 mg/dl; non-high-density lipoprotein  
<  100 mg/dl, smoking abstinence, blood pressure 
< 140/90 mm Hg, regular physical activity = at least 
20 minutes twice a week of intensive activity, normal 
body mass index = 20.0–25.0 kg/m², normal waist cir-
cumference – women < 80 cm or men < 94 cm
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of  individuals who attempted to lose weight was 
similar in both groups (DM(+): 37.6% vs. DM(–): 
33%; p = 0.15). The proportion of patients reporting 
engagement in physical activity aimed at weight 
loss was low and similar between both subgroups 
(DM(+): 21% vs. DM(–): 20.5%; p = 0.85).
Figure 5. Total number of therapeutic goals attained 
in patients with (A) and without (B) diabetes mel-
litus. Therapeutic goals: low-density lipoproteins 
cholesterol < 70 mg/dl; non-high-density lipoprotein  
<  100 mg/dl, smoking abstinence, blood pres-
sure< 140/90 mm Hg, regular physical activity = at 
least 20 minutes twice a week of intensive activity, nor-
mal body mass index = 20.0–25.0 kg/m², normal waist 
circumference – women < 80 cm or men < 94 cm and  
HbA1c < 7.0% for patients with diabetes mellitus
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Figure 3. Proportion of patients with and without diabetes mellitus reaching different target goals of low-density 
lipoprotein cholesterol (A) and non-high-density lipoprotein cholesterol (B)
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Discussion
Our study of  goal attainment in coronary pa-
tients with or without DM provided several im-
portant findings. First, despite a very high CV risk, 
the  mean number of  achieved goals was low in 
patients with and without DM. Second, diabetic or 
lipid goals revealed moderate rates of attainment 
in subjects with DM. Third, BMI, WC and physical 
activity revealed poor control, especially in DM pa-
tients. Fourth, about 6% (44 patients) of partici-
pants had previously undetected DM. Finally, drug 
therapies of dyslipidemia and DM are not optimal 
and need to be improved.
We present the  most recent and comprehen-
sive findings on the  attainment of  therapeutic 
goals in Polish patients since the ESC 2016 guide-
lines [5].
Our study sample was a relatively large group 
of  patients with myocardial infarction or PCI as 
major index events. Patients with DM constitut-
ed one third of all individuals, with slightly high-
er mean age, similar gender distribution and 
significantly increased rates of  obesity and CKD 
compared to non-DM patients. The great majori-
ty of patients with DM were treated with oral an-
tihyperglycemic medication, but the target HbA1c 
was reached in only 60%. Twenty-nine percent 
of  all participants in the  recent EUROASPIRE-V 
registry (EAV) [9] had DM with a higher rate in in-
sulin treatment (EAV: 32%) and slightly lower rate 
of patients with HbA1c target (54%).
There were 6.3% of patients with undetected 
DM during the index event hospitalization, which 
was mostly diagnosed in ambulatory outpatients. 
This screening failure was a cause of delay in di-
agnosis and more intensive treatment or lifestyle 
modifications. Moreover, one-third of  patients 
in the  DM(–) group had increased fasting plas-
ma glucose at the  prospective visit, suggesting 
a pre-diabetes state. This is even more interesting 
and important as those individuals would need 
intensive lifestyle modification to prevent or de-
lay development of DM. Given that most patients 
in both groups had overweight or obesity and did 
not reach the recommended physical activity tar-
get, it is very probable that a considerable number 
of  those patients will develop DM in the  future. 
Undetected pre-diabetes or DM is quite common 
in patients with IHD [16] and it is associated with 
an unfavorable prognosis [17]. HbA1c is a test his-
torically used for glycemic control, which helps to 
identify individuals with increased risk of micro-
vascular complications [18].
The target BP was achieved in less than half 
of the patients with DM in spite of more intensive 
antihypertensive therapy. Additionally, the  rates 
of  CKD and obesity were significantly higher in 
patients with DM compared to non-DM patients. 
It suggests that hypertension is more advanced 
and difficult to control compared to normoglyce-
mic patients [19, 20].
The rates of primary and secondary lipid goal 
attainment were significantly higher in patients 
with DM compared to non-DM subjects. Still, 
the  LDL target was achieved only in one in two 
(DM+) or three (DM–) patients. There were no dif-
ferences in statin use between the  two groups. 
In spite of a very high CV risk of all patients, ro-
suvastatin was used only in one fifth of patients 
and atorvastatin was the most popular lipid-low-
ering drug. The prevalence of ezetimibe was very 
low in both subgroups and fibrates were used 
more frequently in DM. Finally, the rate of hyper-
triglyceridemia was higher in patients with DM. 
Only one in three patients used a  specific lipid- 
lowering diet with a  slightly better rate among 
diabetic patients. Those findings are consistent 
with previous reports on the mechanisms of dys-
lipidemia in DM  [21]. Obesity and DM are asso-
ciated mainly with harmful changes in the quali-
ty (not the quantity) of  LDL particles and higher 
levels of triglycerides [22]. This may explain better 
rates of LDL-C and non-HDL-C goal attainment in 
patients with DM, while scheduled lipid-lowering 
therapy was similar between both subgroups. An-
other potential explanation could be better real 
compliance of individuals with DM to medical rec-
ommendations. In the EAV study, the rates of LDL 
goal achievement in all participants (29%) and pa-
tients with DM (39%) were even worse compared 
to our study groups  [9]. Moreover, the  results 
of the EA-IV [23] focused on patients with a pre-
viously known DM showed a  similar attainment 
of BP target < 140/90 mm Hg (53%), HbA1c goal 
(53%) but significantly lower rate of  LDL-C goal 
achievement (28%).
As expected, the rates of  lifestyle goal attain-
ment were alarming in both groups, especially in 
subjects with DM. An unhealthy lifestyle is a major 
risk factor for the development of DM [24]. Most 
patients reported making an attempt to maintain 
their weight target, but only one third of both sub-
groups reported aiming at weight loss. The num-
ber of patients reporting engagement in physical 
activity in order to lose weight was very small 
and similar in both subgroups. The rates of over-
weight and obesity in our study group with DM 
were higher compared to the overall rates in EAV 
(overweight 44%, obesity 38%) [9]. Although pa-
tients with an early stage of obesity without vas-
cular or metabolic complications may have similar 
prognosis to non-obese individuals [25], obesity is 
the most important factor leading to DM.
Our study provided the most recent results on 
a  real-life therapeutic effects in secondary pre-
vention among Polish patients. The main strength 
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of our multicenter study is that it was performed 
in cardiac centers of various reference levels using 
standardized interviews rather than retrospective 
medical records only. The survey was extensive 
and comparable with results of  a  large cross- 
sectional EAV study [9].
The final list of  medical centers enrolling pa-
tients did not cover all the regions of Poland and 
therefore we cannot state that it was a  nation-
wide epidemiologic study representative for Po-
land. All the participants were volunteers in a pro-
spective visit and survey of  their cardiovascular 
health. This is an obvious bias as the study group 
consisted of patients with an  interest in CV pre-
vention, suggesting that our results on therapeu-
tic goal attainment in everyday practice might be 
even worse. Moreover, our invitation was limited 
only to patients hospitalized due to acute coro-
nary syndrome or a  revascularization procedure. 
Moreover, patients at higher risk who died within 
the first months after hospitalization might have 
presented even worse attainment of  therapeutic 
goals. The retrospective data on study patients is 
based on medical records with all their imperfec-
tions, including the diagnosis of DM and the pri-
mary allocation to one of  the  subgroups. For 
the same reason we do not have patients’ HbA1c 
taken in the index hospitalization (not performed 
routinely), which would be used for a comparison 
with a  prospective test. For logistic reasons, we 
did not perform OGTT at the prospective visit in all 
patients, which limits our knowledge on the cur-
rent glucose state in the subgroup without DM.
In conclusion, this study provides the most re-
cent and comprehensive results on secondary pre-
vention among Polish coronary patients. A  great 
majority of patients with DM in secondary preven-
tion do not achieve treatment goals, particularly 
regarding lifestyles. Although lipid goal attainment 
is better in DM, the management of all risk factors 
needs to be improved. Routine screening for DM 
in coronary patients without known DM should 
become routine. Patients with DM need more in-
tensive DM treatment as only 60% reached the di-
abetic goal. Smoking, obesity and low physical ac-
tivity are the most important adverse lifestyles to 
be improved in both patients with and without DM.
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